Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andy Smith

Set Alert for Articles By Andy Smith

Latest From Andy Smith

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

 

 

Sales & Earnings Vaccines

J.P. Morgan Stockwatch: No Substitute For M&A

Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.

 

M & A Advisory Committees

Stockwatch: Hopes For Fireworks But Expectations For Goldilocks

With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.

Companies Financing

Time Is Money: Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?

Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.

Business Strategies Deals

Stockwatch: Alexion, United Therapeutics, Intercept And "Alternative Facts"

Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?

Sales & Earnings Commercial

Stockwatch: Limited Acquisition Headroom At Specialty Pharma

Debt-fueled acquisitions helped Teva, Shire and Allergan report well-received fourth-quarter earnings. But sector circumstances have changed since 2016 and the ability to grow by debt-funded acquisition is now severely restricted.

M & A Sales & Earnings
See All
UsernamePublicRestriction

Register